David L. Lacey

CIK: 0001734422

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)5 (100.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

RCUS

Arcus Biosciences, Inc.

Director

NRIX

Nurix Therapeutics, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (5 total)

RCUS
Arcus Biosciences, Inc.
Jun 11, 2026
Award(A)
Direct
5.7K shares-
NRIX
Nurix Therapeutics, Inc.
May 15, 2026
Award(A)
Director Stock Option (right to buy)
Direct
31.3K shares-
RCUS
Arcus Biosciences, Inc.
Jun 10, 2025
Award(A)
Direct
13.3K shares-
NRIX
Nurix Therapeutics, Inc.
May 19, 2025
Award(A)
Director Stock Option (right to buy)
Direct
25K shares-
RCUS
Arcus Biosciences, Inc.
Jan 23, 2025
Award(A)
Stock Option (right to buy)
Direct
5K shares-

		Type	Shares	Price		Ownership
Jun 11, 2026	RCUS Arcus Biosciences, Inc.	Award(A)	5,700	-	$0	Direct
May 15, 2026	NRIX Nurix Therapeutics, Inc.	Award(A) Director Stock Option (right to buy)	31,250	-	-	Direct
Jun 10, 2025	RCUS Arcus Biosciences, Inc.	Award(A)	13,300	-	-	Direct
May 19, 2025	NRIX Nurix Therapeutics, Inc.	Award(A) Director Stock Option (right to buy)	25,000	-	-	Direct
Jan 23, 2025	RCUS Arcus Biosciences, Inc.	Award(A) Stock Option (right to buy)	5,000	-	-	Direct

1-5 of 5 transactions

About Lacey David L.

Lacey David L. (SEC CIK 0001734422) files insider reports with the SEC as Director of Arcus Biosciences, Inc. (RCUS) and Director of Nurix Therapeutics, Inc. (NRIX).

Signal8 holds 5 ownership filings by Lacey David L., all Form 4s, filed between Jan 27, 2025 and Jun 12, 2026. Those filings report 5 transactions, from Jan 23, 2025 to Jun 11, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Lacey David L.'s filings is in HAYWARD, CA.

Recent filings by Lacey David L.

Jun 11, 2026: Grant or award of RCUS shares (Form 4, code A).
May 15, 2026: Grant or award of NRIX derivative securities (Form 4, code A).
Jun 10, 2025: Grant or award of RCUS shares (Form 4, code A).
May 19, 2025: Grant or award of NRIX derivative securities (Form 4, code A).
Jan 23, 2025: Grant or award of RCUS derivative securities (Form 4, code A).

Other insiders filing for Arcus Biosciences, Inc. (RCUS)

Azoy Alexander, Chief Accounting Officer
Jaen Juan C., President
Lambert Nicole, Director
Machado Patrick, Director
KANEKO YASUNORI, Director
Tang Carolyn C., General Counsel

How to read Form 4 transaction codes